RARRES2 and polycystic ovary syndrome: The gene expression of Rarres2 was unchanged in the uterus of the VD3-treated control group, whereas was higher in PCOS rats (Figure 5A, p < 0.05), and decreased to the control level in PCOS rats treated with VD3.